Letter--Value-Driven Treatment Decisions: Need of the Hour for Relapsed/Refractory Multiple Myeloma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31456499.
- Also identified by DOI 10.18553/jmcp.2019.25.9.1027 and PMC identifier 10398141.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
No funding was involved in the writing of this letter. Medhekar, Sapra, Majer, Harrison, and Tekle are employees of and stockholders in Amgen.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Multiple Myeloma
- Neoplasm Recurrence, Local